Regeneron Pharmaceut (REGN) 372.03 $REGN
4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
Eric Dutram - Zacks Investment Research - Fri Jun 10, 12:15PM CDT
It was a rough week for the biotechnology ETF (IBB). Which stocks pushed this key sector fund lower for the week?
BIIB: 246.13 (-4.33), BMRN: 81.10 (-1.84), SRPT: 19.95 (-1.04), ALXN: 135.61 (-2.63), IBB: 267.60 (-5.98), REGN: 372.03 (-9.05)
Biotech Stock Roundup: Biogen Slips on MS Results, ASCO Data in Focus
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 1:38PM CDT
Although focus was on data presentation at ASCO, investors were disappointed with Biogen's (BIIB) results on its highly-watched multiple sclerosis treatment.
BIIB: 246.13 (-4.33), SRPT: 19.95 (-1.04), ALXN: 135.61 (-2.63), AMGN: 154.78 (-2.00), ABBV: 61.00 (+0.25), REGN: 372.03 (-9.05), CELG: 102.91 (-3.22)
Regeneron Pharmaceuticals Falls 1.47% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Jun 08, 12:24PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $383.98 to a high of $394.80. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $393.21 on volume of 473,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
REGN: 372.03 (-9.05)
Stock Market News for June 08, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 9:10AM CDT
Benchmarks closed mostly in the green on Tuesday following gains in energy stocks
BIIB: 246.13 (-4.33), VRTX: 91.49 (-1.00), PXD: 159.55 (-4.65), ALXN: 135.61 (-2.63), HAL: 44.38 (-1.12), EOG: 81.56 (-3.02), AMGN: 154.78 (-2.00), ILMN: 141.62 (-1.80), XOM: 89.98 (-0.69), COP: 44.51 (-2.06), JUNO: 42.98 (-2.55), CVX: 101.98 (-0.83), OXY: 75.45 (-0.15), REGN: 372.03 (-9.05)
Regeneron, Sanofi Report Positive Dupilumab Phase III Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 8:52AM CDT
Regeneron (REGN) and Sanofi reported that a phase III study on dupilumab in moderate-to-severe atopic dermatitis patients met the primary and secondary endpoints.
ANIP: 52.05 (-1.64), BMY: 72.65 (-0.08), SNY: 39.41 (-1.45), REGN: 372.03 (-9.05)
Regeneron and Sanofi Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
PR Newswire - Mon Jun 06, 12:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a one-year Phase 3 study, known as LIBERTY AD CHRONOS, evaluating investigational dupilumab met its primary and key secondary endpoints. In the study, dupilumab with topical corticosteroids (TCS) was compared to TCS alone in moderate-to-severe atopic dermatitis (AD) adult patients. Patients in the study were inadequately controlled by topical corticosteroids (TCS) with or without topical calcineurin inhibitors (TCI). Dupilumab with TCS significantly improved measures of overall disease severity at 16 and 52 weeks, when compared to placebo with TCS.
SAN: 4.32 (-0.27), SNY: 39.41 (-1.45), REGN: 372.03 (-9.05)
Regeneron Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
PR Newswire - Thu Jun 02, 6:25PM CDT
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies.
REGN: 372.03 (-9.05)
Regeneron Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 2.04%
Comtex SmarTrend(R) - Wed Jun 01, 12:05PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $395.14 to a high of $408.35. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $400.47 on volume of 468,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
REGN: 372.03 (-9.05)
SCRS Announces the Site Study Dashboard Initiative in Collaboration with ARCO and Many Other Industry Stakeholders
PR Newswire - Wed Jun 01, 9:00AM CDT
The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, continues to ensure the site's voice is heard and positively influencing decisions of industry stakeholders announces the launch of Site Study Dashboard initiative. The following companies are participating: Allergan, Amgen, AstraZeneca, Bio Optronics (Clinical Conductor CTMS), Bristol-Myers Squibb, Center Point Clinical Services, Clinical Ink, Covance, DrugDev, EMD Serono, Fisher Clinical Services, goBalto, Greenphire, HealthCarePoint, INC Research, inVentiv Health, Janssen Pharmaceuticals, Lilly, Merck, Merge, Nimblify, Novartis, Oracle, PAREXEL, PPD, PRA, Quintiles, Regeneron Pharmaceuticals, Sanofi, Vertex and multiple sites from around the globe. This initiative will be co-chaired by representatives from Allergan, Quintiles and Apostle Clinical Trials.
AGN: 240.93 (-6.47), AMGN: 154.78 (-2.00), BMY: 72.65 (-0.08), REGN: 372.03 (-9.05), NVS: 78.94 (-1.57)
Regeneron Reports Interim Data on Cholesterol Lowering Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 9:00AM CDT
Regeneron (REGN) presented positive interim data from a phase II proof-of-concept study on evinacumab for homozygous familial hypercholestrolemia.
ANIP: 52.05 (-1.64), AMGN: 154.78 (-2.00), SNY: 39.41 (-1.45), REGN: 372.03 (-9.05)
Regeneron Presents Positive Interim Data from Phase 2 Proof-of-Concept Study of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia
PR Newswire - Tue May 31, 8:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that positive preliminary results from an ongoing proof-of-concept study of evinacumab (REGN1500) in patients with Homozygous Familial Hypercholestrolemia (HoFH) were presented at the 84th European Atherosclerosis Society (EAS) Congress in Innsbruck, Austria. The interim data from the first 4 patients treated in this study showed that evinacumab added to current lipid-lowering therapy reduced low-density lipoprotein cholesterol (LDL-C) levels by an additional 55 percent (mean reduction; range 25 to 90 percent) at week 4 compared to baseline. Evinacumab is an investigational monoclonal antibody to angiopoietin-like protein 3 (ANGPTL3). ANGPTL3 acts as an inhibitor of lipoprotein lipase and endothelial lipase, and appears to play a central role in lipoprotein metabolism.
REGN: 372.03 (-9.05)
Regeneron Selected by Society for Science & the Public as New Sponsor of the Science Talent Search
PR Newswire - Thu May 26, 7:30AM CDT
Society for Science & the Public (Society) today announced that Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is the new title sponsor of the Science Talent Search. Selected through a competitive process that garnered interest from the nation's leading companies and philanthropists, Regeneron will become only the third sponsor in 75 years of the nation's oldest and most prestigious high school science competition.
REGN: 372.03 (-9.05)
New Cholesterol Treatment Now Available for Canadians
CNW Group - Tue May 24, 10:02AM CDT
As 8 in 10 Canadian GPs identify the need for new cholesterol treatment options, Canadian Patients now have access to PRALUENTTM
SAN: 4.32 (-0.27), SNY: 39.41 (-1.45), REGN: 372.03 (-9.05)
Watch for Regeneron Pharmaceuticals to Potentially Pullback After Gaining 1.73% Yesterday
Comtex SmarTrend(R) - Mon May 23, 12:10PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $384.31 to a high of $396.99. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $394.01 on volume of 596,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
REGN: 372.03 (-9.05)
Stock Market News for May 13, 2016
Zacks Equity Research - Zacks Investment Research - Fri May 13, 9:10AM CDT
Benchmarks closed mixed after shares of Apple declined to a two-year low, which in turn had a negative impact on the S&P 500 and Nasdaq
MU: 12.14 (-0.37), BIIB: 246.13 (-4.33), AMGN: 154.78 (-2.00), INTC: 32.04 (+0.10), AGN: 240.93 (-6.47), T: 40.33 (+0.24), YHOO: 36.83 (-0.52), GILD: 84.45 (-1.32), GOOGL: 733.19 (-9.33), VZ: 52.67 (+0.72), AAPL: 98.83 (-0.82), CTL: 26.96 (-0.04), AVGO: 160.82 (-3.32), MA: 95.21 (-1.81), REGN: 372.03 (-9.05)
Regeneron Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 2.29%
Comtex SmarTrend(R) - Thu May 12, 12:14PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $362.39 to a high of $375.00. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of $370.20 on volume of 470,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
REGN: 372.03 (-9.05)
5 Toxic Stocks to Discard from Your Portfolio
Zacks Equity Research - Zacks Investment Research - Mon May 09, 11:56AM CDT
A toxic stock is basically the one which trades at a price not supported by its fundamental strength.
NDLS: 9.85 (-0.04), ZAYO: 27.40 (-0.72), REGN: 372.03 (-9.05), VSAT: 72.46 (-1.63), ENT: 7.35 (-0.12)
Avalanche (AAVL) Reports Wider-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Mon May 09, 9:16AM CDT
Avalanche Biotechnologies, Inc. (AAVL) reported a loss of 57 cents per share in the first quarter of 2016,.
SHPG: 177.10 (-6.85), AAVL: 4.14 (-0.18), NKTR: 15.80 (-0.48), REGN: 372.03 (-9.05)
Regeneron (REGN) Tops Q1 Earnings, Ups 2016 Eylea View
Zacks Equity Research - Zacks Investment Research - Thu May 05, 9:42AM CDT
Regeneron Pharmaceuticals (REGN) reported better-than-expected first-quarter 2016 earnings of $1.45 per share.
ANIP: 52.05 (-1.64), SNY: 39.41 (-1.45), REGN: 372.03 (-9.05)
4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
Eric Dutram - Zacks Investment Research - Fri Jun 10, 12:15PM CDT
It was a rough week for the biotechnology ETF (IBB). Which stocks pushed this key sector fund lower for the week?
BIIB: 246.13 (-4.33), BMRN: 81.10 (-1.84), SRPT: 19.95 (-1.04), ALXN: 135.61 (-2.63), IBB: 267.60 (-5.98), REGN: 372.03 (-9.05)
Biotech Stock Roundup: Biogen Slips on MS Results, ASCO Data in Focus
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 1:38PM CDT
Although focus was on data presentation at ASCO, investors were disappointed with Biogen's (BIIB) results on its highly-watched multiple sclerosis treatment.
BIIB: 246.13 (-4.33), SRPT: 19.95 (-1.04), ALXN: 135.61 (-2.63), AMGN: 154.78 (-2.00), ABBV: 61.00 (+0.25), REGN: 372.03 (-9.05), CELG: 102.91 (-3.22)
Regeneron Pharmaceuticals Falls 1.47% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Jun 08, 12:24PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $383.98 to a high of $394.80. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $393.21 on volume of 473,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
REGN: 372.03 (-9.05)
Stock Market News for June 08, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 9:10AM CDT
Benchmarks closed mostly in the green on Tuesday following gains in energy stocks
BIIB: 246.13 (-4.33), VRTX: 91.49 (-1.00), PXD: 159.55 (-4.65), ALXN: 135.61 (-2.63), HAL: 44.38 (-1.12), EOG: 81.56 (-3.02), AMGN: 154.78 (-2.00), ILMN: 141.62 (-1.80), XOM: 89.98 (-0.69), COP: 44.51 (-2.06), JUNO: 42.98 (-2.55), CVX: 101.98 (-0.83), OXY: 75.45 (-0.15), REGN: 372.03 (-9.05)
Regeneron, Sanofi Report Positive Dupilumab Phase III Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 8:52AM CDT
Regeneron (REGN) and Sanofi reported that a phase III study on dupilumab in moderate-to-severe atopic dermatitis patients met the primary and secondary endpoints.
ANIP: 52.05 (-1.64), BMY: 72.65 (-0.08), SNY: 39.41 (-1.45), REGN: 372.03 (-9.05)
Regeneron and Sanofi Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
PR Newswire - Mon Jun 06, 12:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a one-year Phase 3 study, known as LIBERTY AD CHRONOS, evaluating investigational dupilumab met its primary and key secondary endpoints. In the study, dupilumab with topical corticosteroids (TCS) was compared to TCS alone in moderate-to-severe atopic dermatitis (AD) adult patients. Patients in the study were inadequately controlled by topical corticosteroids (TCS) with or without topical calcineurin inhibitors (TCI). Dupilumab with TCS significantly improved measures of overall disease severity at 16 and 52 weeks, when compared to placebo with TCS.
SAN: 4.32 (-0.27), SNY: 39.41 (-1.45), REGN: 372.03 (-9.05)
Regeneron Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
PR Newswire - Thu Jun 02, 6:25PM CDT
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies.
REGN: 372.03 (-9.05)
Regeneron Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 2.04%
Comtex SmarTrend(R) - Wed Jun 01, 12:05PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $395.14 to a high of $408.35. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $400.47 on volume of 468,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
REGN: 372.03 (-9.05)
SCRS Announces the Site Study Dashboard Initiative in Collaboration with ARCO and Many Other Industry Stakeholders
PR Newswire - Wed Jun 01, 9:00AM CDT
The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, continues to ensure the site's voice is heard and positively influencing decisions of industry stakeholders announces the launch of Site Study Dashboard initiative. The following companies are participating: Allergan, Amgen, AstraZeneca, Bio Optronics (Clinical Conductor CTMS), Bristol-Myers Squibb, Center Point Clinical Services, Clinical Ink, Covance, DrugDev, EMD Serono, Fisher Clinical Services, goBalto, Greenphire, HealthCarePoint, INC Research, inVentiv Health, Janssen Pharmaceuticals, Lilly, Merck, Merge, Nimblify, Novartis, Oracle, PAREXEL, PPD, PRA, Quintiles, Regeneron Pharmaceuticals, Sanofi, Vertex and multiple sites from around the globe. This initiative will be co-chaired by representatives from Allergan, Quintiles and Apostle Clinical Trials.
AGN: 240.93 (-6.47), AMGN: 154.78 (-2.00), BMY: 72.65 (-0.08), REGN: 372.03 (-9.05), NVS: 78.94 (-1.57)
Regeneron Reports Interim Data on Cholesterol Lowering Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 9:00AM CDT
Regeneron (REGN) presented positive interim data from a phase II proof-of-concept study on evinacumab for homozygous familial hypercholestrolemia.
ANIP: 52.05 (-1.64), AMGN: 154.78 (-2.00), SNY: 39.41 (-1.45), REGN: 372.03 (-9.05)
Regeneron Presents Positive Interim Data from Phase 2 Proof-of-Concept Study of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia
PR Newswire - Tue May 31, 8:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that positive preliminary results from an ongoing proof-of-concept study of evinacumab (REGN1500) in patients with Homozygous Familial Hypercholestrolemia (HoFH) were presented at the 84th European Atherosclerosis Society (EAS) Congress in Innsbruck, Austria. The interim data from the first 4 patients treated in this study showed that evinacumab added to current lipid-lowering therapy reduced low-density lipoprotein cholesterol (LDL-C) levels by an additional 55 percent (mean reduction; range 25 to 90 percent) at week 4 compared to baseline. Evinacumab is an investigational monoclonal antibody to angiopoietin-like protein 3 (ANGPTL3). ANGPTL3 acts as an inhibitor of lipoprotein lipase and endothelial lipase, and appears to play a central role in lipoprotein metabolism.
REGN: 372.03 (-9.05)
Regeneron Selected by Society for Science & the Public as New Sponsor of the Science Talent Search
PR Newswire - Thu May 26, 7:30AM CDT
Society for Science & the Public (Society) today announced that Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is the new title sponsor of the Science Talent Search. Selected through a competitive process that garnered interest from the nation's leading companies and philanthropists, Regeneron will become only the third sponsor in 75 years of the nation's oldest and most prestigious high school science competition.
REGN: 372.03 (-9.05)
New Cholesterol Treatment Now Available for Canadians
CNW Group - Tue May 24, 10:02AM CDT
As 8 in 10 Canadian GPs identify the need for new cholesterol treatment options, Canadian Patients now have access to PRALUENTTM
SAN: 4.32 (-0.27), SNY: 39.41 (-1.45), REGN: 372.03 (-9.05)
Watch for Regeneron Pharmaceuticals to Potentially Pullback After Gaining 1.73% Yesterday
Comtex SmarTrend(R) - Mon May 23, 12:10PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $384.31 to a high of $396.99. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $394.01 on volume of 596,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
REGN: 372.03 (-9.05)
Stock Market News for May 13, 2016
Zacks Equity Research - Zacks Investment Research - Fri May 13, 9:10AM CDT
Benchmarks closed mixed after shares of Apple declined to a two-year low, which in turn had a negative impact on the S&P 500 and Nasdaq
MU: 12.14 (-0.37), BIIB: 246.13 (-4.33), AMGN: 154.78 (-2.00), INTC: 32.04 (+0.10), AGN: 240.93 (-6.47), T: 40.33 (+0.24), YHOO: 36.83 (-0.52), GILD: 84.45 (-1.32), GOOGL: 733.19 (-9.33), VZ: 52.67 (+0.72), AAPL: 98.83 (-0.82), CTL: 26.96 (-0.04), AVGO: 160.82 (-3.32), MA: 95.21 (-1.81), REGN: 372.03 (-9.05)
Regeneron Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 2.29%
Comtex SmarTrend(R) - Thu May 12, 12:14PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $362.39 to a high of $375.00. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of $370.20 on volume of 470,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
REGN: 372.03 (-9.05)
5 Toxic Stocks to Discard from Your Portfolio
Zacks Equity Research - Zacks Investment Research - Mon May 09, 11:56AM CDT
A toxic stock is basically the one which trades at a price not supported by its fundamental strength.
NDLS: 9.85 (-0.04), ZAYO: 27.40 (-0.72), REGN: 372.03 (-9.05), VSAT: 72.46 (-1.63), ENT: 7.35 (-0.12)
Avalanche (AAVL) Reports Wider-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Mon May 09, 9:16AM CDT
Avalanche Biotechnologies, Inc. (AAVL) reported a loss of 57 cents per share in the first quarter of 2016,.
SHPG: 177.10 (-6.85), AAVL: 4.14 (-0.18), NKTR: 15.80 (-0.48), REGN: 372.03 (-9.05)
Regeneron (REGN) Tops Q1 Earnings, Ups 2016 Eylea View
Zacks Equity Research - Zacks Investment Research - Thu May 05, 9:42AM CDT
Regeneron Pharmaceuticals (REGN) reported better-than-expected first-quarter 2016 earnings of $1.45 per share.
ANIP: 52.05 (-1.64), SNY: 39.41 (-1.45), REGN: 372.03 (-9.05)
